Gavin Marx
Overview
Explore the profile of Gavin Marx including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
40
Citations
1063
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Harb M, Kamath A, Marx G, Gupta S
Asia Pac J Clin Oncol
. 2023 Sep;
20(1):87-92.
PMID: 37771144
Purpose: Endoscopic ultrasound-guided gastro-enterostomy (EUS-GE) is a relatively novel technique that has been shown to require less re-intervention than standard endoscopic enteral stenting for gastric outlet obstruction and is less...
12.
Sweeney C, Martin A, Stockler M, Begbie S, Cheung L, Chi K, et al.
Lancet Oncol
. 2023 Mar;
24(4):323-334.
PMID: 36990608
Background: The interim analysis of the ENZAMET trial of testosterone suppression plus either enzalutamide or standard nonsteroidal antiandrogen therapy showed an early overall survival benefit with enzalutamide. Here, we report...
13.
Chan A, Ruiz-Borrego M, Marx G, Jo Chien A, Rugo H, Brufsky A, et al.
Breast
. 2023 Jan;
67:94-101.
PMID: 36702070
Background: Neratinib is an irreversible pan-HER tyrosine kinase inhibitor approved for HER2-positive early-stage and metastatic breast cancer. Diarrhea is the most frequent side effect and the most common reason for...
14.
Lok S, de Boer R, Baron-Hay S, Button P, Devitt B, Forster B, et al.
Int J Cancer
. 2022 Aug;
152(2):267-275.
PMID: 36005450
The pertuzumab study in the neoadjuvant setting for HER2+ nonmetastatic breast cancer in Australia (PeRSIA-ML39622) is an analysis of safety and effectiveness data from the pertuzumab patient registry. Although the...
15.
Choi J, Hughes T, Marx G, Boyages J, Rutovitz J, Hasovits C, et al.
Breast J
. 2022 Jun;
2022:1199245.
PMID: 35711899
Introduction: The Oncotype DX test is a genomic assay that generates a Recurrence Score (RS) predicting the 10-year risk of recurrence and response to adjuvant chemotherapy in ER+/HER2- breast cancer...
16.
Mak B, Lin H, Kwan E, Fettke H, Tran B, Davis I, et al.
BMC Med
. 2022 Mar;
20(1):112.
PMID: 35331214
Background: Both changes in circulating lipids represented by a validated poor prognostic 3-lipid signature (3LS) and somatic tumour genetic aberrations are individually associated with worse clinical outcomes in men with...
17.
Lin H, Mak B, Yeung N, Huynh K, Meikle T, Mellett N, et al.
EBioMedicine
. 2021 Oct;
72:103625.
PMID: 34656931
Background: Intrinsic resistance to androgen receptor signalling inhibitors (ARSI) occurs in 20-30% of men with metastatic castration-resistant prostate cancer (mCRPC). Ceramide metabolism may have a role in ARSI resistance. Our...
18.
Lin H, Yeung N, Hastings J, Croucher D, Huynh K, Meikle T, et al.
Cancers (Basel)
. 2021 Oct;
13(19).
PMID: 34638448
Circulating lipids or cytokines are associated with prognosis in metastatic castration-resistant prostate cancer (mCRPC). This study aimed to understand the interactions between lipid metabolism and immune response in mCRPC by...
19.
Clarke S, Burge M, Feeney K, Gibbs P, Jones K, Marx G, et al.
PLoS One
. 2020 Mar;
15(3):e0229900.
PMID: 32142532
Background: In spite of demonstrating prognostic and possibly predictive benefit in retrospective cohorts and meta-analyses of cancer populations, including colorectal cancer (CRC), prospective evaluation of the relationship between neutrophil to...
20.
Timmins H, Li T, Kiernan M, Baron-Hay S, Marx G, Boyle F, et al.
Support Care Cancer
. 2020 Jan;
28(9):4459-4466.
PMID: 31925531
Purpose: Chemotherapy-induced peripheral neuropathy (CIPN) is a dose-limiting side-effect of neurotoxic cancer treatment impacting on long-term quality of life. Symptoms include numbness, tingling, and pain, affecting the distal extremities. However,...